To evaluate whether these diarylheptanoid derivatives suppress EGFR expression and inhibit the tumor growth in distinct EGFR-mutant, TKI-resistant lung cancer models, we performed a growth inhibitory screening by treating curcumin, MTH-3, and 14 diarylheptanoid derivatives in EGFR-mutant H1650 cells (Fig. 2, B and C), which cells are known to be intrinsically resistant to EGFR kinase inhibition but sensitize to EGFR protein depletion (12). This evidence concerns the gene EGFR and lung cancer.